WO2007117161A1 - Substituted ring fused azines and their use in cancer therapy - Google Patents

Substituted ring fused azines and their use in cancer therapy Download PDF

Info

Publication number
WO2007117161A1
WO2007117161A1 PCT/NZ2007/000077 NZ2007000077W WO2007117161A1 WO 2007117161 A1 WO2007117161 A1 WO 2007117161A1 NZ 2007000077 W NZ2007000077 W NZ 2007000077W WO 2007117161 A1 WO2007117161 A1 WO 2007117161A1
Authority
WO
WIPO (PCT)
Prior art keywords
azines
cancer therapy
ring fused
substituted ring
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NZ2007/000077
Other languages
English (en)
French (fr)
Inventor
William Alexander Denny
Bruce Charles Baguley
Elaine Shirley Marshall
Hamish Scott Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Priority to JP2009504144A priority Critical patent/JP2009533338A/ja
Priority to US12/296,377 priority patent/US20090318479A1/en
Priority to AU2007235751A priority patent/AU2007235751A1/en
Priority to CA002648323A priority patent/CA2648323A1/en
Priority to EP07747705A priority patent/EP2004637A4/en
Publication of WO2007117161A1 publication Critical patent/WO2007117161A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/NZ2007/000077 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy Ceased WO2007117161A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009504144A JP2009533338A (ja) 2006-04-07 2007-04-04 置換環縮合アジンおよび癌治療におけるそれらの使用
US12/296,377 US20090318479A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy
AU2007235751A AU2007235751A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy
CA002648323A CA2648323A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy
EP07747705A EP2004637A4 (en) 2006-04-07 2007-04-04 SUBSTITUTED RING-CONDENSED AZINES AND THEIR USE IN CANCER THERAPY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ546477 2006-04-07
NZ546477A NZ546477A (en) 2006-04-07 2006-04-07 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy

Publications (1)

Publication Number Publication Date
WO2007117161A1 true WO2007117161A1 (en) 2007-10-18

Family

ID=38581368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2007/000077 Ceased WO2007117161A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Country Status (8)

Country Link
US (1) US20090318479A1 (https=)
EP (1) EP2004637A4 (https=)
JP (1) JP2009533338A (https=)
CN (1) CN101460490A (https=)
AU (1) AU2007235751A1 (https=)
CA (1) CA2648323A1 (https=)
NZ (1) NZ546477A (https=)
WO (1) WO2007117161A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2013182546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
WO2016068580A3 (en) * 2014-10-29 2016-08-18 Dong-A Socio Holdings Co., Ltd. Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
WO2017034377A1 (en) * 2015-08-26 2017-03-02 Dong-A St Co., Ltd. Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
WO2021155426A1 (en) * 2020-02-04 2021-08-12 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
CN107721982B (zh) * 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
MX2023003273A (es) 2020-09-21 2023-04-26 Landos Biopharma Inc Ligandos de nlrx1.
CN114044769B (zh) * 2021-11-25 2023-12-12 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN117247374B (zh) * 2022-06-10 2026-03-17 四川科伦博泰生物医药股份有限公司 一种bcl-xl抑制剂及其制药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1290700A (en) * 1998-12-02 2000-06-19 Pfizer Products Inc. Methods and compositions for restoring conformational stability of a protein of the p53 family
DK1088818T3 (da) * 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] HERMECZ I. ET AL., XP003022292, accession no. STN Database accession no. (1994:457466) *
DATABASE CA [online] LAL B. ET AL., XP003022291, accession no. STN Database accession no. (1994:457466) *
DATABASE CA [online] LEE E.S. ET AL., XP003022295, accession no. STN Database accession no. (142:219453) *
DATABASE CA [online] SUI Z. ET AL., XP003022293, accession no. STN Database accession no. (126:264070) *
DATABASE CA [online] XP003022289, accession no. STN Database accession no. (137:154942) *
DATABASE CA [online] XP003022290, accession no. STN Database accession no. (1973:29771) *
DATABASE CA [online] XP003022294, accession no. STN Database accession no. (135:344500) *
HETEROCYCLES, vol. 37, no. 2, 1994, pages 903 - 914 *
HETEROCYCLIC COMMUNICATIONS, vol. 10, no. 4-5, 2004, pages 325 - 330 *
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 34, no. 1, 1997, pages 153 - 156 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 55, no. 17, 1990, pages 5117 - 5124 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2013182546A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
US9458133B2 (en) 2013-03-11 2016-10-04 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
US9834550B2 (en) 2014-10-29 2017-12-05 Dong-A St Co., Ltd. Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
KR20170072943A (ko) * 2014-10-29 2017-06-27 동아에스티 주식회사 히스톤 라이신 탈메틸화 촉매 활성을 조절하기 위한 신규 피리도피리미디논 화합물
CN107001358A (zh) * 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
WO2016068580A3 (en) * 2014-10-29 2016-08-18 Dong-A Socio Holdings Co., Ltd. Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
AU2015340215B2 (en) * 2014-10-29 2018-11-15 Dong-A St Co., Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs)
RU2684396C2 (ru) * 2014-10-29 2019-04-09 Донг-А Ст Ко., Лтд. Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS)
KR101978899B1 (ko) * 2014-10-29 2019-05-15 동아에스티 주식회사 히스톤 라이신 탈메틸화 촉매 활성을 조절하기 위한 신규 피리도피리미디논 화합물
WO2017034377A1 (en) * 2015-08-26 2017-03-02 Dong-A St Co., Ltd. Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
WO2021155426A1 (en) * 2020-02-04 2021-08-12 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer

Also Published As

Publication number Publication date
AU2007235751A1 (en) 2007-10-18
US20090318479A1 (en) 2009-12-24
JP2009533338A (ja) 2009-09-17
NZ546477A (en) 2009-04-30
CN101460490A (zh) 2009-06-17
EP2004637A1 (en) 2008-12-24
CA2648323A1 (en) 2007-10-18
EP2004637A4 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
TW200716646A (en) (S)-N-methylnaltrexone
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
IL184617A0 (en) Dr5 antibodies and uses thereof
MX277822B (es) Derivados de urea de tropano, su preparacion y su aplicacion terapeutica.
MY158257A (en) Forms of rifaximin and uses thereof
TW200606162A (en) Pyrazolopyridine derivatives
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
WO2007125331A3 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2011056566A3 (en) Compounds and methods for treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780020464.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747705

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007235751

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2648323

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009504144

Country of ref document: JP

Ref document number: 12296377

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007235751

Country of ref document: AU

Date of ref document: 20070404

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007747705

Country of ref document: EP